Skip to main content
. 2017 Dec 9;8(69):113472–113493. doi: 10.18632/oncotarget.23052

Figure 2. Inhibition of PTTG1 expression impairs proliferation of melanoma cells sensitive or resistant to dabrafenib.

Figure 2

(A) Melanoma cells were treated with dabrafenib (DAB) or DMSO alone (–) for 48 h and then cell lysates were analyzed by immunoblotting using antibodies against PTTG1, or against β-tubulin as a loading control. The results are representative of three independent experiments. (B) and (C) Melanoma cells were transiently transfected with siPTTG1 or siCTRL and 24 h later incubated with dabrafenib (DAB) or DMSO alone (–). After 48 h of culture, cell extracts were prepared and analyzed by immunoblotting using antibodies against PTTG1 or against β-tubulin. The results are representative of three independent experiments. (D) Melanoma cells were transfected with siPTTG1 or siCTRL and three and six days later assessed for proliferation using the MTT assay. Data are expressed in terms of percentage of cell growth inhibition of siPTTG1-transfected cells with respect to matched siCTRL-transfected cells. Each value represents the arithmetic mean of four independent experiments. Bars, SEM. **P < 0.01 and *P < 0.05 siPTTG1-transfected cells vs matched siCTRL-transfected cells; ∫∫P < 0.01 and ∫P < 0.05 dabrafenib-resistant cells vs matched drug-sensitive cells.